Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.8481
-0.0259 (-2.96%)
At close: Oct 15, 2025, 4:00 PM EDT
0.8481
0.00 (0.00%)
Pre-market: Oct 16, 2025, 5:14 AM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $174.00K in the quarter ending May 31, 2025, with 107.14% growth. This brings the company's revenue in the last twelve months to $615.92K, up 49.85% year-over-year. In the fiscal year ending August 31, 2024, Lexaria Bioscience had annual revenue of $464.28K with 105.24% growth.
Revenue (ttm)
$615.92K
Revenue Growth
+49.85%
P/S Ratio
23.45
Revenue / Employee
$87,989
Employees
7
Market Cap
18.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LEXX News
- 6 days ago - Lexaria Bioscience Corp. Provides Strategic Update - Accesswire
- 16 days ago - Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 19 days ago - Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - TheNewswire
- 26 days ago - Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain - Accesswire
- 7 weeks ago - Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference - TheNewswire
- 2 months ago - Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - Accesswire
- 2 months ago - GLP-1 "Arms Race" Broadens to Include Dozens of Companies - Accesswire
- 2 months ago - Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study - TheNewswire